Table 2.
Summary of anti-inflammatory treatment strategies.
| Treatment | Mechanism Target | Clinical benefit? | Mortality decrease? |
|---|---|---|---|
| Compound 21 | AT2R agonist (renin-angiotensin system) | ✓ | X |
| Losartan | AT1R antagonist (renin-angiotensin system) | X | X |
| Baricitinib | JAK1/2 | ✓ | X |
| Ruxolitinib | JAK1/2 | X | X |
| Dornase Alfa | Neutrophil extracellular traps (mucous) | X (?) | X (?) |
| Heparin | Blood clotting | ✓* | ✓* |
| Methylprednisolone | Inflammatory cytokine production | ✓* | ✓* |
| Dexamethasone | Inflammatory cytokine production | ✓ | ✓ |
✓ - The drug produced the respective column’s effect. X - The drug failed to produce the respective column’s effect. ‐* - Clinical trials of this drug either failed to exceed 100 participants or lacked any blinding.